Drugs / Oxybutynin
Oxybutynin
also known as
Oxybutynin Chloride · Ditropan XL · Oxytrol · Ditropan · 5058 · Anturol; Oxybutynin Gel 3% · BAY839380 · Contimin 2.5 · +28 more
Small molecule targets CHRM2, CHRM3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed overactive bladder 1 milestone | |||||
| Filed | US (FDA) | Ditropan XL | overactive bladder | — | “IMPAX's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Ditropan XL (Oxybutynin Chloride) Tablets, 15 mg.” amneal.com ↗ |
| Approved Indication not stated 4 milestones | |||||
| Label expansion | US (FDA) | DITROPAN XL | — | 2004-06-30 | fda.gov ↗ |
| Approved | EU (EMA) | Kentera (previously Oxybutynin Nicobrand) | — | 2004-06-15 | europa.eu ↗ |
| Label expansion | US (FDA) | DITROPAN | — | 2003-04-15 | fda.gov ↗ |
| Approved | US (FDA) | DITROPAN | — | 1975-07-16 | fda.gov ↗ |
Trials 58
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03205605 | Jan 2018 → Nov 2019 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 18 trials · 1 missed | ||||||
| Phase 1 | NCT00926926 | Jun → Jul 2009 | — | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00752141 | Sep → Oct 2008 | — | Watson Pharmaceuticals | Completed | Missed primary |
| Phase 1 | NCT00501267 | Jun → Aug 2007 | overactive bladder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00649272 | Jan 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00650481 | Dec 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648843 | Dec 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649129 | Jul → Aug 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649727 | Jul 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07577661 | Sep 2026 → Sep 2028 expected | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05944965 | Dec 2023 → Jun 2025 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT05550246 | May 2022 → Dec 2024 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 213 trials · 3 met primary | ||||||
| Phase 2 | NCT07391878 | Feb 2026 → Dec 2027 expected | overactive bladder | Trigone Pharma Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05933603 | Sep 2023 → Jun 2026 overdue | Down syndrome, obstructive sleep apnea syndrome | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05102396 | Sep 2022 → Jun 2024 | isolated hyperchlorhidrosis, sweat gland disorder | Samantha Rodrigues Camargo Neves de Moura | Unknown | No outcome recorded |
| Phase 2 | NCT04600336 | Oct 2021 → Feb 2024 | prostate carcinoma | Alliance for Clinical Trials in Oncology | Completed | Met primary |
| Phase 2 | NCT04526353 | Sep 2020 → Feb 2028 expected | male reproductive system disorder | University Hospital, Bordeaux | Recruiting | No outcome recorded |
| Phase 2 | NCT04445688 | Jul → Dec 2020 | obstructive sleep apnea syndrome | Apnimed | Completed | Met primary |
| Phase 2 | NCT04449133 | Jul → Oct 2020 | obstructive sleep apnea syndrome | Istituto Auxologico Italiano | Completed | Met primary |
| Phase 2 | NCT03919955 | Sep 2019 → Sep 2023 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03845023 | Mar → Oct 2019 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
| Phase 2 | NCT02240459 | Aug 2016 → Jan 2020 | cognitive impairment with or without cerebellar ataxia, overactive bladder | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT01370811 | Aug 2011 → Sep 2012 | — | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00816972 | Apr → Jun 2005 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT00990886 | Apr 2004 → Jan 2005 | — | Ortho-McNeil Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT04394143 | Oct 2020 → Jul 2021 | obstructive sleep apnea syndrome | Raphael Heinzer | Completed | Missed primary |
| Phase 314 trials · 2 met primary | ||||||
| Phase 3 | NCT07027020 | Jan 2026 → Jan 2028 expected | spina bifida | Central Hospital, Nancy, France | Recruiting | No outcome recorded |
| Phase 3 | NCT06106529 | Oct 2024 → Jan 2029 expected | female breast carcinoma | Reinier de Graaf Groep | Recruiting | No outcome recorded |
| Phase 3 | NCT03952299 | Sep 2021 → Dec 2026 expected | overactive bladder | University of California, Davis | Recruiting | No outcome recorded |
| Phase 3 | NCT02961790 | Dec 2016 → Apr 2018 | ductal breast carcinoma in situ, lobular breast carcinoma in situ | Academic and Community Cancer Research United | Completed | Met primary |
| Phase 3 | NCT01050114 | Aug 2013 → Jul 2018 | overactive bladder | Christopher Patrick Smith | Unknown | No outcome recorded |
| Phase 3 | NCT01855256 | Jun 2013 → Feb 2014 | isolated hyperchlorhidrosis | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT04534491 | May 2010 → Jun 2011 | overactive bladder | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00909181 | Mar 2009 → Jul 2010 | overactive bladder | Antares Pharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00350636 | Jun 2006 → May 2007 | overactive bladder | Watson Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00338624 | May 2004 → Jun 2005 | urinary system disorder | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00269724 | Mar → Sep 1997 | overactive bladder | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00269750 | Jul 1996 → Feb 1997 | urinary bladder disorder | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00304499 | Dec 1995 → Dec 1996 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00293839 | ? → Dec 2002 | overactive bladder | Alza Corporation | Completed | No outcome recorded |
| Phase 412 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT07280468 | Mar 2026 → Jan 2030 expected | Down syndrome, obstructive sleep apnea syndrome | University of Arizona | Recruiting | No outcome recorded |
| Phase 4 | NCT06295562 | Nov 2024 → Oct 2025 | obstructive sleep apnea syndrome | China Medical University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04090190 | Oct 2019 → May 2021 | overactive bladder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01824420 | Mar 2013 → Feb 2017 | overactive bladder | Buddhist Tzu Chi General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01192568 | May 2011 → Aug 2023 | overactive bladder | AbbVie | Completed | Missed primary |
| Phase 4 | NCT01310712 | Dec 2010 → Feb 2011 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01796548 | Dec 2008 → Dec 2010 | overactive bladder | Janssen-Cilag Ltd.,Thailand | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03877289 | Oct 2008 → Jul 2014 | cystitis | University of Calgary | Completed | No outcome recorded |
| Phase 4 | NCT00613327 | Sep 2007 → Jun 2008 | overactive bladder | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT00411437 | Dec 2006 → Jun 2007 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00224029 | Dec 2004 → Dec 2005 | overactive bladder | Watson Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT00224146 | May 2004 → May 2005 | overactive bladder | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06966778 | Sep 2025 → Dec 2028 expected | cancer | National Taiwan University Hospital | Recruiting | No outcome recorded |
| — | NCT02704013 | Apr 2016 → Dec 2017 | overactive bladder | Children's Hospital Zagreb | Unknown | No outcome recorded |
| — | NCT02633371 | Feb → Jun 2016 | isolated hyperchlorhidrosis | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02973659 | May 2015 → Aug 2016 | — | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT00892450 | May 2009 → Sep 2014 | Parkinson disease, overactive bladder | US Department of Veterans Affairs | Completed | No outcome recorded |
| — | NCT01118429 | Jan 2007 → Jun 2009 | extraoral halitosis due to methanethiol oxidase deficiency, isolated hyperchlorhidrosis | Grupo de Cirurgia Vascular | Completed | No outcome recorded |
| Comparator or background therapy40 trials | ||||||
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1 | NCT06162065 Background | Nov 2023 → Jan 2024 | overactive bladder | Universidad de Valparaiso | Unknown | No outcome recorded |
| Phase 1 | NCT00649259 Comparator | Oct → Nov 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT03720353 Comparator | Dec 2018 → Dec 2019 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02908529 Comparator | Sep 2016 → Dec 2017 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06181591 Comparator | Apr 2024 → Apr 2025 | overactive bladder | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04115878 Comparator | Oct 2020 → Dec 2022 | Down syndrome, obstructive sleep apnea syndrome | University of Arizona | Completed | No outcome recorded |
| Phase 2 | NCT01328015 Comparator | Mar → May 2010 | isolated hyperchlorhidrosis | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT00749632 Comparator | Jul 2007 → Oct 2008 | overactive bladder | FemmePharma Global Healthcare, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00170768 Comparator | Feb → May 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT07114640 Comparator | Aug 2025 → Dec 2028 expected | overactive bladder | Far Eastern Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06737016 Background | Nov 2024 → May 2026 overdue | posterior urethral valve | Mansoura University | Recruiting | No outcome recorded |
| Phase 3 | NCT05658874 Background | Dec 2022 → Dec 2024 | interstitial cystitis, levator syndrome | Jocelyn Fitzgerald | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05637671 Comparator | Feb 2022 → Dec 2023 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02099695 Comparator | Dec 2015 → Jan 2016 | isolated hyperchlorhidrosis | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03050827 Comparator | May 2014 → Aug 2017 | diabetic polyneuropathy | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 3 | NCT02538302 Comparator | Jul 2013 → Jul 2015 | nocturnal enuresis | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01557244 Comparator | Jul 2012 → Nov 2019 | urinary bladder disorder | Pfizer | Completed | Met primary |
| Phase 3 | NCT01716624 Comparator | May 2011 → Mar 2012 | low compliance bladder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT01187498 Comparator | Jan 2005 → Oct 2009 | overactive bladder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT07679282 Comparator | Sep 2026 → Mar 2030 expected | obstructive sleep apnea syndrome | Sairam Parthasarathy | Recruiting | No outcome recorded |
| Phase 4 | NCT04909255 Comparator | Mar 2021 → Aug 2022 | Sjogren syndrome, overactive bladder | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02176642 Comparator | Aug 2014 → Nov 2016 | urinary bladder disorder | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT01423838 Comparator | Sep 2011 → Sep 2012 | overactive bladder | Adana Numune Training and Research Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01178827 Comparator | Aug 2010 → Mar 2011 | overactive bladder | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01126424 Comparator | Apr → Dec 2010 | — | Astellas Pharma Inc | Completed | Missed primary |
| Phase 4 | NCT00629642 Comparator | Mar 2008 → Jan 2011 | multiple sclerosis, spinal cord disorder | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00800462 Comparator | Mar 2008 → Jun 2012 | overactive bladder, spinal cord injury | Toronto Rehabilitation Institute | Completed | No outcome recorded |
| Phase 4 | NCT00547378 Comparator | Oct 2007 → Aug 2016 | overactive bladder | MedtronicNeuro | Completed | No outcome recorded |
| Phase 4 | NCT01899794 Comparator | Oct 2007 → Apr 2013 | female stress incontinence | Jewish General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00431041 Comparator | Dec 2006 → Feb 2008 | overactive bladder | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00224016 Comparator | Dec 2004 → Apr 2007 | urinary bladder disorder | Watson Pharmaceuticals | Completed | No outcome recorded |
| — | NCT07259148 Comparator | Nov 2025 → Jan 2026 overdue | overactive bladder | Emilio José Dávila Álvarez | Active not recruiting | No outcome recorded |
| — | NCT07668232 Comparator | Jan → Dec 2025 | posterior urethral valve | South Valley University | Completed | No outcome recorded |
| — | NCT05100017 Comparator | Sep 2021 → Jun 2025 overdue | nephrolithiasis, ureterolithiasis | Northwestern University | Active not recruiting | No outcome recorded |
| — | NCT07081906 Comparator | Feb → Jul 2019 | overactive bladder | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Completed | No outcome recorded |
| — | NCT02483793 Comparator | Jul 2015 → Dec 2016 | urinary system disorder | Phoenix Children's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01829425 Comparator | Apr 2013 → Oct 2017 | urinary bladder disorder | University of New Mexico | Completed | No outcome recorded |
| — | NCT01477736 Comparator | Jan 2009 → Nov 2010 | spinal cord injury | Centro de Reabilitação e Readaptação Dr. Henrique Santillo | Completed | No outcome recorded |
| — | NCT00223821 Background | Sep 2003 → Nov 2008 | — | US Department of Veterans Affairs | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2013-01-25 | Merck Sharp & Dohme LLC | Regulatory FDA Approves OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women merck.com ↗ |
| 2012-11-09 | Merck Sharp & Dohme LLC | Regulatory Merck to Continue Work with FDA for OXYTROL® as an Over-the-Counter Treatment for Overactive Bladder in Women merck.com ↗
Today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed that the U.S. Food and Drug Administration’s (FDA) Nonprescription Drug Advisory Committee proposed that the FDA consider labeling modifications as part of their review of OXYTROL (oxybutynin transdermal system) as an over-the-counter (OTC) treatment for overactive bladder (OAB) in women. |
| 2007-05-09 | Impax Laboratories, LLC | Regulatory IMPAX Receives Final FDA Approval for Generic Ditropan(R) XL 5 mg and 10 mg amneal.com ↗
IMPAX Laboratories, Inc. (OTC: IPXL) ("IMPAX" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for generic versions of Ditropan(R) XL, (Oxybutynin Chloride) 5 mg and 10 mg Extended-release Tablets. |
| 2006-11-10 | Impax Laboratories, LLC | Regulatory IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Ditropan(R) XL 15 mg amneal.com ↗
The FDA also awarded the Company first-to-file status and 180-day market exclusivity for this product. |
| 2005-02-02 | Impax Laboratories, LLC | Regulatory IMPAX Receives Tentative FDA Approval for Generic Version of Ditropan XL; First Approval in 2005 amneal.com ↗
IMPAX Laboratories, Inc. (NASDAQ:IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to the Company's Abbreviated New Drug Application (ANDA) for a generic version of Ditropan(R) XL (Oxybutynin Chloride) 5, 10 and 15 mg Extended Release Tablets. |
All press releases naming this drug 11 releases
Evidence & citations 42 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxybutynin | “adults with loud habitual snoring took atomoxetine plus oxybutynin for 10 days before bedtime at full adult doses (80 and 5 mg, respectively; half-dose run-in on days 1-3) and...” PMID 40471069 ↗ Sep 202593“Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.” PMID 36861433 ↗ Jul 2023 “This study evaluated the efficacy and safety of AD036 (atomoxetine 80 mg and oxybutynin 5 mg) in the treatment of OSA.” PMID 35551600 ↗ May 2022 “Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg” NCT00547378 ↗ “TRG-200 KIT, a novel intravesical sustained-release delivery system containing oxybutynin.” NCT07391878 ↗ “comparing 4 mg reboxetine plus 5 mg oxybutynin (Reb-Oxy) vs placebo in patients with OSA.” PMID 34543665 ↗ Sep 2021 “Oxybutynin is primarily indicated for the treatment of overactive bladder syndrome.” NCT07668232 ↗ “Overactive Bladder Medication( Trospium/Oxybutynin/Detrol vs. Mirabegron)” NCT05658874 ↗ “0.5 mg/kg (max 40 mg) of atomoxetine and 5mg oxybutynin taken nightly.” NCT07280468 ↗ “Oxybutynin (Ditropan Extended Release or equivalent generic)” NCT01829425 ↗ “flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel)” NCT01796548 ↗ |
| Known as | 5058 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Anturol; Oxybutynin Gel 3% | “Anturol; Oxybutynin Gel 3%” NCT00909181 ↗ |
| Known as | BAY839380 | “Oxybutynin (Oxytrol, BAY839380)” NCT04534491 ↗ |
| Known as | Contimin 2.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Contimin 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Cystrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Ditropan | “The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge...” NCT00269750 ↗1“Oxybutynin (Ditropan) ER 5mg QD” NCT01824420 ↗ |
| Known as | Ditropan XL | “The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets...” NCT00649129 ↗2“A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride)...” NCT00338624 ↗ “Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder” NCT00293839 ↗ |
| Known as | Gelnique | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Kentera | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Kentera (previously oxybutynin nicobrand) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Lyrinel xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | MJ 4309-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | NSC-759108 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | OROS oxybutynin | “The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge...” NCT00269750 ↗ |
| Known as | Oxibutinina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | OXY-ER | “flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel)” NCT01796548 ↗ |
| Known as | OXY-TDS | “oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA)” PMID 17187655 ↗ Dec 2006 |
| Known as | Oxybutynin (Ditropan Extended Release or equivalent generic) | “Oxybutynin (Ditropan Extended Release or equivalent generic)” NCT01829425 ↗ |
| Known as | Oxybutynin Chloride | “OROS® (oxybutynin chloride) 5 mg tablets, one to six tablets per day (5 mg/day to 30 mg/day) as a single morning oral dose for 11 days up to 70 days, and Ditropan (oxybutynin...” NCT00269750 ↗17“This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin...” NCT00800462 ↗ “A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride)...” NCT00338624 ↗ “Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.” NCT06181591 ↗ “Transdermally administered oxybutynin chloride topical gel 10% (OTG) has a low propensity for anticholinergic adverse effects” PMID 22909146 ↗ Oct 2012 “Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg” NCT00648843 ↗ “10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.” NCT01192568 ↗ “Individually-titrated, extended-release oxybutynin chloride with management of side-effects.” NCT00223821 ↗ “Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally” NCT01796548 ↗ “Oxybutynin Chloride Extended-release Tablets 5 mg” NCT00650481 ↗ “Oxybutynin chloride 15 mg once daily for 12 weeks” NCT00990886 ↗ |
| Known as | Oxybutynin Cl | “Drug: Oxybutynin Cl” NCT00800462 ↗ |
| Known as | oxybutynin ER | “One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.” NCT05637671 ↗ |
| Known as | Oxybutynin Hydrochloride | “Drug: Oxybutynin Hydrochloride” NCT07027020 ↗ |
| Known as | oxybutynin IR | “oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days” NCT01178827 ↗ |
| Known as | oxybutynin transdermal delivery system | “oxybutynin transdermal delivery system (Oxytrol(r))” NCT00224146 ↗ |
| Known as | oxybutynin transdermal system | “oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA)” PMID 17187655 ↗ Dec 2006 |
| Known as | oxybutynin-TDS | “oxybutynin transdermal system (oxybutynin-TDS) in spinal cord injury patients with neurogenic detrusor overactivity and incontinence” PMID 19628264 ↗ Jul 2009 |
| Known as | Oxybutynine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Oxytrol | “oxybutynin transdermal delivery system (Oxytrol(r))” NCT00224146 ↗ |
| Known as | Oxytrol for women | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Oxytrol(r) | “oxybutynin transdermal delivery system (Oxytrol(r))” NCT00224146 ↗ |
| Known as | PMS-Oxybutynin | “The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.).” NCT04526353 ↗ |
| Known as | Pollakisu | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Promictuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Tropax | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Known as | Urimin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231 ↗ |
| Action | Inhibit | “Oxybutynin is a parasympatholytics with relaxant effect on bladder detrusor muscle by action on muscarinic antagonist.” NCT01328015 ↗2“Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1231 ↗ “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL1231 ↗ |
| Modality | Small molecule | — CHEMBL1231 ↗ |
| Route | Other | “1.3, 2.6, 3.9 mg/day transdermal” NCT00224016 ↗ |
| Target | CHRM2 | “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL1231 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1231 ↗ |